Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Characteristics of reference sample groups by location

More »

Table 1 Expand

Figure 1.

Hemoglobin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval and cutoff for DAIDS grade one severity (vertical dashed line).

More »

Figure 1 Expand

Table 2.

Hematology results, U.S.-based comparison intervals and out of range (OOR) values

More »

Table 2 Expand

Figure 2.

Neutrophil intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval and cutoff for DAIDS grade one severity (vertical dashed line).

More »

Figure 2 Expand

Figure 3.

Eosinophil count intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.

More »

Figure 3 Expand

Figure 4.

CD4 count intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval and cutoff for DAIDS grade one severity (vertical dashed line).

More »

Figure 4 Expand

Figure 5.

Total bilirubin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval and cutoff for DAIDS grade one severity (vertical dashed line).

More »

Figure 5 Expand

Figure 6.

Direct bilirubin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.

More »

Figure 6 Expand

Table 3.

Chemistry results, U.S.-based comparison intervals, and out of range (OOR) values

More »

Table 3 Expand

Figure 7.

IgG intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.

More »

Figure 7 Expand

Figure 8.

LDH intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.

More »

Figure 8 Expand

Table 4.

Analyte results and frequency of “adverse events” graded against western-derived DAIDS AE cutoffs*

More »

Table 4 Expand